Patent Application
20210060217
The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to sensors as well as diagnostic and control systems for wound therapy applications.
Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” “vacuum-assisted closure,” and “topical negative-pressure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
There is also widespread acceptance that cleansing a tissue site can be highly beneficial for new tissue growth. For example, a wound can be washed out with a stream of liquid solution, or a cavity can be washed out using a liquid solution for therapeutic purposes. These practices are commonly referred to as “irrigation” and “lavage” respectively. “Instillation” is another practice that generally refers to a process of slowly introducing fluid to a tissue site and leaving the fluid for a prescribed period of time before removing the fluid. For example, instillation of topical treatment solutions over a wound bed can be combined with negative-pressure therapy to further promote wound healing by loosening soluble contaminants in a wound bed and removing infectious material. As a result, soluble bacterial burden can be decreased, contaminants removed, and the wound cleansed.
While the clinical benefits of negative-pressure therapy and instillation therapy are widely known, improvements to therapy systems, components, and processes may benefit healthcare providers and patients.
New and useful systems, apparatuses, and methods for treating tissue in a negative-pressure therapy environment are set forth in the appended claims. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter.
For example, in some embodiments, a system for treating a tissue site may include a dressing, a diagnostic module, a negative-pressure source, a first fluid source, and a controller. The dressing may be adapted to be placed on the tissue site, and the diagnostic module may be adapted to be positioned adjacent the dressing. The diagnostic module may include a first sensor configured to detect a pH level of fluid present at the tissue site and to generate a first output based on the detected pH level. The diagnostic module may also include a transceiver configured to transmit the first output. The negative-pressure source may be adapted to be fluidly coupled to the dressing. The first fluid source may be adapted to be fluidly coupled to the dressing and to deliver a first fluid to the dressing. The controller may be configured to receive the first output and control the negative-pressure source and the fluid source based on the first output. The system may further include a second fluid source adapted to be fluidly coupled to the dressing and to deliver a second fluid to the dressing, wherein the controller may be further configured to provide an alert to indicate which of the first fluid and the second fluid should be delivered to the dressing. Additionally or alternatively, the system may further include a first treatment source configured to provide a first therapeutic compound to the first fluid and a second treatment source configured to provide a second therapeutic compound to the first fluid, wherein the controller is configured to control the first treatment source and the second treatment source based on the first output.
In other example embodiments, a system for treating a tissue site may include a dressing, a diagnostic module, and a therapy unit. The dressing may be adapted to be placed on the tissue site, and the diagnostic module may comprise a first sensor device adapted to be positioned adjacent the dressing. The first sensor device may include a first sensor configured to detect a first variable associated with the tissue site and to generate a first output based on the detected first variable. The first sensor device may also include a transceiver configured to transmit the first output generated by the first sensor. The therapy unit may include a negative-pressure source adapted to be fluidly coupled to the dressing, a fluid source adapted to be fluidly coupled to the dressing, a communication device, and a processing unit. The communication device may be configured to receive the first output from the transceiver. The processing unit may be configured to alter an operational parameter of the system based on the first output received by the communication device.
In yet other example embodiments, a dressing for administering to a tissue site may include a tissue interface, a diagnostic module, and a cover. The tissue interface may be adapted to be placed proximate to the tissue site, and the diagnostic module may be adapted to be positioned proximate to the tissue interface. The diagnostic module may include a primary sensor array and a transceiver. The primary sensor array may include a first sensor configured to detect a first variable related to the tissue site and to generate a first output based on the detected first variable, and the transceiver may be configured to transmit the first output generated by the first sensor. The cover may be adapted to be placed over the tissue interface and the diagnostic module.
In further example embodiments, a method for treating a tissue site may include applying a dressing to the tissue site, coupling a therapy unit to the dressing, and activating the therapy unit. The dressing may include a tissue interface, a diagnostic module, and a cover. The diagnostic module may include a first sensor configured to detect a first variable related to the tissue site and to generate a first output based on the detected first variable and a transceiver configured to transmit the first output. The cover may be adapted to be placed over the tissue interface and the diagnostic module. The therapy unit may include a negative-pressure source, a fluid source, a communication device, and a processing unit. The communication device may be configured to receive the first output from the transceiver, and the processing unit may be configured to receive the first output and alter an operational parameter of the therapy unit. The therapy unit may be activated to exchange data with the transceiver and to apply at least one of negative-pressure and a fluid from the fluid source to the dressing according to the operational parameter.
Objectives, advantages, and a preferred mode of making and using the claimed subject matter may be understood best by reference to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments.
The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.
The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.
The term “tissue site” in this context broadly refers to a wound, defect, or other treatment target located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be applied to a tissue site to grow additional tissue that may be harvested and transplanted.
The therapy system 100 may include a negative-pressure supply, and may include or be configured to be coupled to a distribution component, such as a dressing. In general, a distribution component may refer to any complementary or ancillary component configured to be fluidly coupled to a negative-pressure supply in a fluid path between a negative-pressure supply and a tissue site. A distribution component is preferably detachable, and may be disposable, reusable, or recyclable. For example, a dressing 102 may be fluidly coupled to a negative-pressure source 104, as illustrated in
In some embodiments, a dressing interface, such as dressing interface 107, may facilitate coupling the negative-pressure source 104 to the dressing 102. For example, such a dressing interface may be a T.R.A.C.® Pad or Sensa T.R.A.C.® Pad available from KCI of San Antonio, Tex. In some embodiments, the dressing 102 may include a dressing interface 107 as well as a second dressing interface 117. The therapy system 100 may optionally include a fluid container, such as a container 112, coupled to the dressing 102 and to the negative-pressure source 104.
The therapy system 100 may also include a source of instillation solution. For example, a solution source 114 may be fluidly coupled to the dressing 102, as illustrated in the example embodiment of
Additionally, the therapy system 100 may include sensors to measure operating parameters and provide feedback signals to a controller 110 indicative of the operating parameters. As illustrated in
Components may be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. For example, components may be fluidly coupled through a fluid conductor, such as a tube. A “tube,” as used herein, broadly includes a tube, pipe, hose, conduit, or other structure with one or more lumina adapted to convey a fluid between two ends. Typically, a tube is an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. In some embodiments, components may also be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Moreover, some fluid conductors may be molded into or otherwise integrally combined with other components. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts. For example, one or more tubes, such as conduits 122 and 128, may mechanically and fluidly couple the dressing 102 to the container 112 in some embodiments.
In general, components of the therapy system 100 may be coupled directly or indirectly. For example, the negative-pressure source 104 may be directly coupled to the controller 110, and may be indirectly coupled to the dressing interface 107 through the container 112 by conduit 126 and conduit 128. The first sensor 120 may be fluidly coupled to the dressing 102 directly or indirectly by conduit 121 and conduit 122. Additionally, the positive pressure source 116 may be coupled indirectly to the dressing interface 107 through the solution source 114 and the instillation regulator 115 by fluid conductors 132, 134, and 138. Alternatively, the positive pressure source 116 may be coupled indirectly to the second dressing interface 117 through the solution source 114 and the instillation regulator 115 by fluid conductors 132, 134, and 139.
The fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy and instillation are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.
In general, exudates and other fluids flow toward lower pressure along a fluid path. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a source of negative pressure or further away from a source of positive pressure. Conversely, the term “upstream” implies something relatively further away from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components herein. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.
“Negative pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 102. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between −5 mm Hg (−667 Pa) and −500 mm Hg (−66.7 kPa). Common therapeutic ranges are between −75 mm Hg (−9.9 kPa) and −300 mm Hg (−39.9 kPa).
A negative-pressure supply, such as the negative-pressure source 104, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure supply may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative-pressure source 104 may be combined with the controller 110 and other components into a therapy unit. A negative-pressure supply may also have one or more supply ports configured to facilitate coupling and de-coupling the negative-pressure supply to one or more distribution components.
The tissue interface 108 can be generally adapted to contact a tissue site. The tissue interface 108 may be partially or fully in contact with the tissue site. If the tissue site is a wound, for example, the tissue interface 108 may partially or completely fill the wound, or may be placed over the wound. The tissue interface 108 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site. For example, the size and shape of the tissue interface 108 may be adapted to the contours of deep and irregular shaped tissue sites. Moreover, any or all of the surfaces of the tissue interface 108 may have projections or an uneven, course, or jagged profile that can induce strains and stresses on a tissue site, which can promote granulation at the tissue site.
In some embodiments, the tissue interface 108 may be a manifold. A “manifold” in this context generally includes any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site under pressure. For example, a manifold may be adapted to receive negative pressure from a source and distribute negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate delivering fluid across a tissue site.
In some illustrative embodiments, the pathways of a manifold may be interconnected to improve distribution or collection of fluids across a tissue site. In some illustrative embodiments, a manifold may be a porous foam material having interconnected cells or pores. For example, cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid channels. Liquids, gels, and other foams may also include or be cured to include apertures and fluid pathways. In some embodiments, a manifold may additionally or alternatively comprise projections that form interconnected fluid pathways. For example, a manifold may be molded to provide surface projections that define interconnected fluid pathways.
The average pore size of a foam may vary according to needs of a prescribed therapy. For example, in some embodiments, the tissue interface 108 may be a foam having pore sizes in a range of 400-600 microns. The tensile strength of the tissue interface 108 may also vary according to needs of a prescribed therapy. For example, the tensile strength of a foam may be increased for instillation of topical treatment solutions. In one non-limiting example, the tissue interface 108 may be an open-cell, reticulated polyurethane foam such as a GRANUFOAM™ dressing or a V.A.C. VERAFLO™ dressing, both available from Kinetic Concepts, Inc. of San Antonio, Tex.
The tissue interface 108 may be either hydrophobic or hydrophilic. In an example in which the tissue interface 108 may be hydrophilic, the tissue interface 108 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 108 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WHITEFOAM™ dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
The tissue interface 108 may further promote granulation at a tissue site when pressure within the sealed therapeutic environment is reduced. For example, any or all of the surfaces of the tissue interface 108 may have an uneven, coarse, or jagged profile that can induce microstrains and stresses at a tissue site if negative pressure is applied through the tissue interface 108.
In some embodiments, the tissue interface 108 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The tissue interface 108 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the tissue interface 108 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
In some embodiments, the cover 106 may provide a bacterial barrier and protection from physical trauma. The cover 106 may also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The cover 106 may be, for example, an elastomeric film or membrane that can provide a seal adequate to maintain a negative pressure at a tissue site for a given negative-pressure source. The cover 106 may have a high moisture-vapor transmission rate (MVTR) in some applications. For example, the MVTR may be at least 250 g/m{circumflex over ( )}2 per twenty-four hours in some embodiments, measured using an upright cup technique according to ASTM E96/E96M Upright Cup Method at 38° C. and 10% relative humidity (RH). In some embodiments, a MVTR up to 5,000 grams per square meter per twenty-four hours may provide may provide effective breathability and mechanical properties. In some example embodiments, the cover 106 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained.
An attachment device may be used to attach the cover 106 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. The attachment device may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or an entire sealing member of the cover 106. In some embodiments, for example, some or all of the cover 106 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.
A controller, such as the controller 110, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative-pressure source 104. In some embodiments, for example, the controller 110 may be a microcontroller, which generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the negative-pressure source 104, the pressure generated by the negative-pressure source 104, or the pressure distributed to the tissue interface 108, for example. The controller 110 is also preferably configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
Sensors, such as the first sensor 120 and the second sensor 124, are generally known in the art as any apparatus operable to detect or measure a physical phenomenon or property, and generally provide a signal indicative of the phenomenon or property that is detected or measured. For example, the first sensor 120 and the second sensor 124 may be configured to measure one or more operating parameters of the therapy system 100. In some embodiments, the first sensor 120 may be a transducer configured to measure pressure in a pneumatic pathway and convert the measurement to a signal indicative of the pressure measured. In some embodiments, for example, the first sensor 120 may be a piezoresistive strain gauge. The second sensor 124 may optionally measure operating parameters of the negative-pressure source 104, such as the voltage or current, in some embodiments. Preferably, the signals from the first sensor 120 and the second sensor 124 are suitable as an input signal to the controller 110, but some signal conditioning may be appropriate in some embodiments. For example, the signal may need to be filtered or amplified before it can be processed by the controller 110. Typically, the signal is an electrical signal, but may be represented in other forms, such as an optical signal.
The container 112 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudates and other fluids withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluids. In other environments, fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy.
The solution source 114 may also be representative of a container, canister, pouch, bag, or other storage component, which can provide a solution for instillation therapy. Compositions of solutions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, cationic solutions, and isotonic solutions.
The dressing 102 may further include an apparatus containing sensors for measuring one or more conditions or variables present at the dressing 102 and/or tissue site. For example, the dressing 102 may include diagnostic module 140, which may be positioned on, under, within, or between any of the other components of the dressing 102, for example the cover 106 and tissue interface 108. In some embodiments, the diagnostic module 140 may be positioned on or within either or both of the dressing interface 107 and/or second dressing interface 117.
In operation, the tissue interface 108 may be placed within, over, on, or otherwise proximate to a tissue site. The cover 106 may be placed over the tissue interface 108 and sealed to an attachment surface near the tissue site. For example, the cover 106 may be sealed to undamaged epidermis peripheral to a tissue site. Thus, the dressing 102 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 104 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across the tissue site through the tissue interface 108 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site, as well as remove exudates and other fluids from the tissue site, which can be collected in container 112.
As shown in
In some embodiments, the diagnostic module 140 may include a sensor device 142, which may be configured to measure one or more parameters in the environment of the tissue site 150. The one or more parameters measured by the sensor device 142 may be in addition to pressure measurements gathered by one or more pressure sensors, such as the first sensor 120, of the therapy system 100. For example, the sensor device 142 may be configured to detect and/or measure pH of wound exudates, temperature at the tissue site 150 as well as within the dressing 102, oxygen concentration of tissue at the tissue site 150 as well as in the surrounding tissue, humidity within the dressing 102, glucose levels within wound exudates, as well as other parameters. Thus, in some embodiments, the sensor device 142 may include one or more sensors, such as a pH sensor, temperature sensor, humidity sensor, blood sensor, glucose sensor, growth factor sensor, volatile organic compound (VOC) sensor, or another type of sensor. The sensor device 142 may also include a pressure sensor. Additionally, the sensor device 142 may include one or more sensors for detecting and/or measuring various electrolyte levels at a tissue site 150 through electrical resistance sensing.
As previously mentioned, the diagnostic module 140 may also include a communications component, such as communications module 144, for transmitting and receiving data to/from one or more other components of the therapy system 100, such as the therapy unit 101 or controller 110. For example, the communications module 144 may include a transceiver configured to exchange data with a communications device 111 that is part of the controller 110 or therapy unit 101 or electrically coupled to the controller 110. The communications module 144 may be configured to transmit data regarding the parameters detected and/or measured by the sensor device 142 of the diagnostic module 140. In some embodiments, the communications module 144 of the diagnostic module 140 may be configured to wirelessly exchange data with a communications device 111 that is electrically coupled to the controller 110. For example, the communications module 144 of the diagnostic module 140 and the communications device 111 of the controller 110 may be configured to communicate using the Bluetooth® 4.0 protocol. Alternative wireless communication protocols may also be employed, including other Bluetooth® standards, Zigbee®, ANT, Z-WAVE, Wireless USB, or others. Other forms of wireless communication may also be incorporated, such as non-radio frequency technologies such as IrDA and Ultrasonic communications.
Alternatively or additionally, the diagnostic module 140 may be electrically coupled to the therapy unit 101, communications device 111, and/or the controller 110 via one or more wires, and thus the communications module 144 of the diagnostic module 140 may exchange data via a wired connection with the controller 110 related to one or more parameters sensed by the sensor device 142. For example, two or three wires may be implemented, which may provide electrical power to the diagnostic module 140 from the therapy unit 101, or more specifically the controller 110, as well as conduct multiplexed bi-directional signals.
In some embodiments, an optimized wired connection may be included to electrically couple the diagnostic module 140 to the therapy unit 101. In such embodiments, a number of wires may be used, which may in part depend on the number of individual sensors included as part of the sensor device 142 of the diagnostic module 140. Given that multiple individual sensors may be included as part of the sensor device 142, with each of the sensors potentially having different signal and communication requirements, a small interface micro-controller may be included as part of the diagnostic module 140 to reduce the total number of wires required for communication between the sensing device 142 of the diagnostic module 140 and the controller 110 of the therapy unit 101. For example, a micro-controller may be capable of polling the sensors of the diagnostic module 140 and digitizing the data from the sensors so that it can be communicated to the controller 110 of the therapy unit 101. In such embodiments, power for the diagnostic module 140 may be provided through the wired connection, while communications between the diagnostic module 140 and the controller 110 may use a Serial Perpheral Interface bus (SPI) or similar protocol to minimize the total number of wires required. Depending on the power requirements of the particular diagnostic module 140, a system such as a 1-Wire could be used. Incorporating a wired solution for enabling communications between the diagnostic module 140 and the therapy unit 101 may also increase the number and types of sensors that could be used in the sensor device 142 of the diagnostic module 140 by mitigating potential power limitations of using one or more batteries for powering the sensors.
Still referring primarily to
In operation, in response to one or more parameters detected and/or sensed by the sensors of the sensor device 142, the diagnostic module 140 may transmit data from the sensor device 142 via the communications module 144 to the communications device 111 of the therapy unit 101. The controller 110 may receive data, via the communications device 111, from the diagnostic module 140 and process the data to determine one or more factors related to the tissue site 150. Based on one or more parameters measured by the diagnostic module 140, the controller 110 may be able to determine the status and healing trend of the tissue site 150. Based on an assessment of pH data, humidity data, temperature data, and/or data provided by the particular type(s) of sensor(s) included in the sensor device 142 of the diagnostic module 140, the controller 110 may determine a progression of wound healing. For example, a change in a pH measurement may signal a change in the status of the tissue site 150. In some instances, a tissue site, such as a wound, may be considered in a healthy state if the pH of the wound fluids stay within a particular range. Elevated or reduced pH measurements may indicate that a wound is in a chronic or inflammatory state. In some instances, the status of a tissue site 150 may be identified by monitoring increases in measured humidity and/or temperature. For example, if the temperature data indicates that the temperature at the tissue site 150 is increasing, the increasing temperature may be an indication that the wound is infected.
The controller 110 may then alert a user of the therapy system 100 as to the status of the tissue site 150, so that the user may take one or more actions to address or remedy the status of the tissue site 150. In some embodiments, the controller 110 may generate an output or alert to a user in order to direct the user to administer one or more forms of therapy. For example, the controller 110 may indicate via the display unit 103 of the therapy unit 101 that the user should increase fluid instillation therapy as well as administer a first therapeutic compound from the first treatment source 160. Following the administration of the first therapeutic compound and fluid instillation therapy, the therapy system 100 may continue to operate and measure the effects of the administered therapy via one or more parameters measured by the diagnostic module 140. Subsequently, the controller 110 may determine that, based on measurements taken by the diagnostic module 140, the status of the tissue site 150 has changed, and that an adjustment to one or more forms of therapy would be beneficial to the tissue site 150. For example, the controller 110 may generate an output to the user that delivery of the first therapeutic compound from the first treatment source 160 should be suspended, while fluid instillation therapy from the solution source 114 should be increased. The controller 110 may continue to monitor the status of the tissue site 150 through parameters measured by the diagnostic module 140 and indicate proposed therapy adjustments throughout the operation of the therapy system 100.
Furthermore, in some embodiments, the controller 110 may automatically direct that one or more types of therapy to the tissue site 150 could be initiated, adjusted, or stopped. In some embodiments, the controller 110 may automatically make changes to one or more forms of therapy, and thus the adjustments to the therapy may be triggered independently of an operator of the therapy system 100. However, the adjustments to the one or more forms of therapy may be within a set of bounds previously specified by the operator before activating the therapy system 100. In some embodiments, in response to a status of the tissue site 150 as determined by the controller 110, the controller 110 may adjust the application of negative pressure to the tissue site 150. For example, the negative-pressure source 104 may be directed by the controller 110 to reduce or cease delivery of negative pressure to the tissue site 150 for specific time periods, such as while fluid instillation therapy is being administered to the tissue site 150. Furthermore, the controller 110 may adjust the operation of the negative-pressure source 104 to maintain pressure levels within the dressing 102 at desired levels, based on feedback from a pressure sensor included as part of the diagnostic module 140 and/or a pressure sensor located at another portion of the therapy system 100, such as part of first sensor 120. Additionally or alternatively, in response to the status of the tissue site 150, the controller 110 may initiate the instillation of fluid, for example from solution source 114, to the tissue site 150. Further, the controller 110 may adjust one or more properties of the fluid administered to the tissue site 150. For example, in response to a particular status of the tissue site 150 as determined by the controller 110 in response to parameters sensed by the diagnostic module 140, the controller 110 may cause a treatment compound from the first treatment source 160 to be conducted through the first source conduit 164 and added to the instillation fluid being administered to the tissue site 150. Additionally or alternatively, the controller 110 may cause a treatment compound from the second treatment source 162 to be conducted through the second source conduit 166 and added to the instillation fluid being administered to the tissue site 150.
As conditions of the tissue site 150 change over time, the controller 110 may determine a new or changed status of the tissue site 150 based on data received from the diagnostic module 140. As a result, the controller 110 may adjust the therapy being administered to the tissue site 150. For example, in response to the changed status, the controller 150 may stop the delivery of one or both of the first treatment compound and the second treatment compound from the first treatment source 160 and the second treatment source 162, respectively. Furthermore, the controller 110 may stop the delivery of instillation fluid from the solution source 114 altogether, and/or cause the delivery of negative-pressure to the tissue site 150 to cease. Additionally, the controller 110 may provide feedback to a caregiver or the patient.
Furthermore, in some instances, the controller 110 may determine that it would be beneficial to alternate between two forms of fluid instillation therapy. For example, the controller 110 may direct the solution source 114 to direct a first fluid, such as a saline solution, to the tissue site 150 for promotion of granulation at the tissue site 150. The controller 110 may then suspend the operation of the negative-pressure source 104 for a determined period of time to allow the saline solution to remain in contact with the tissue site 150. The controller 110 may also take into account data received from the sensors of the diagnostic module 140 when determining the length of time for allowing the saline solution to remain at the tissue site 150. Following the appropriate period of time, the controller 110 may direct the negative-pressure source 104 to resume administration of negative pressure to the tissue site 150, which may result in the removal of much of the administered saline solution. The controller 110 may then direct that a first therapeutic compound, such as a Prontosan® solution, be delivered from the first treatment source 160 to the tissue site 150. A solution, such as Prontosan solution, may be administered for controlling possible infection or levels of microbes at the tissue site 150. Other types of antimicrobial solutions or other forms of therapeutic substances may also be delivered to the tissue site 150. Once again, the negative-pressure source 104 may be powered down for an appropriate period of time, as determined by the controller 110, to allow the first therapeutic compound to take effect at the tissue site 150. Following the appropriate time period, the negative-pressure source 104 may resume operation and may deliver negative pressure to the tissue site 150, thus removing at least a portion of the first therapeutic compound from the tissue site 150. The controller 110 may also use feedback from the diagnostic module 140 to vary the level of negative pressure supplied by the negative-pressure source 104 to the tissue site 150. It should be noted that the controller 110 may automatically adjust the amount of time either form of treatment fluid remains at the tissue site 150, which may at least partially be due to feedback from the diagnostic module 140. Depending on the condition of the tissue site 150, which may in part be determined based on data received from the diagnostic module 140, the controller 110 may direct that additional cycles of alternating between two or more forms of fluid instillation therapy are warranted.
For example, as previously mentioned, one parameter measured by a sensor of the sensor device 142 of the diagnostic module 140 may be pH. Raised pH of tissue sites, such as wounds, has been shown to be connected with several factors of wound conditions such as slower healing rates, elevated protease activity, and higher oxygen (O2) concentrations. In combination with measurement of other parameters, such as temperature and oxygenation of the tissue site, pH measurements may be used to determine that it would be beneficial to instill a solution that would lower the pH at the tissue site. For example, a pre-prepared solution at a preferred pH, such as 0.9% saline which has a typical pH of 5.5-6, may be included in the solution source 114 of the therapy system 100, for instillation to the tissue site. Solutions that are pH-controlled may also be included in the solution source 114, such as for example Phosphate-buffered Saline (PBS), Dulbecco's Phosphate-buffered Saline (DPBS), Hank's Balanced Salt Solution (HBSS), and Earle's Balanced Salt Solution (EBSS). Alternatively or additionally, a means to dose a standard saline solution to alter its pH may be provided by including a dosing solution in either of the first treatment source 160 or second treatment source 162 for addition to a standard saline solution in the solution source 114. Including a dosing solution, for example in the first treatment source 160, for adjusting the pH of a standard saline solution of the solution source 114 may allow for a solution with variable pH levels to be delivered to the tissue site 150 based on the particular condition of the tissue site 150. In such embodiments, the second treatment source 162 may contain an additional wound healing compound which may be added to the instillation fluid from the solution source 114 based on the interpretation by the controller 110 of diagnostic information from the one or more sensors of the diagnostic module 140. For example, either the first treatment source 160 or the second treatment source 162 may include an antimicrobial agent that may be added to the instillation fluid based on a determination by the controller 110 that an infection exists at the tissue site 150.
As previously mentioned, the sensor device 142 of the diagnostic module 140 may include a temperature sensor, which may be used to track the temperature of the tissue site 150 at one or more locations over time. For example, should the controller 110 receive data from the diagnostic module 140 indicating that the temperature of the tissue site 150 has been increasing for an amount of time, the controller 110 may make the determination that an infection is present at the tissue site 150. In response, the controller 110 may direct that particular treatment compound, such as one from either or both of the first treatment source 160 and second treatment source 162, be administered to the tissue site 150.
In additional or alternative embodiments, the diagnostic module 140 may be configured to monitor the administration of particular therapeutic compounds, such as honey, to the tissue site 150. In such embodiments, the sensor device 142 of the diagnostic module 140 may include a glucose sensor. For example, a form of medical grade honey may be administered from the first treatment source 160 to the tissue site 150. A glucose sensor included as part of the sensor device 142 may be configured to monitor glucose levels at the tissue site 150, and the controller 110 may use such measurements to determine whether levels of glucose fall below a pre-determined threshold or out of a therapeutic range. Based on this feedback from the diagnostic module 140, the controller 110 may then direct that additional honey from the first treatment source 160 be delivered to the tissue site 150.
In some embodiments, the tissue interface 308 may have a periphery 370 surrounding a central portion 372, and a plurality of apertures 374 disposed throughout the periphery 370 and the central portion 372. The tissue interface 308 may also have a border 376 substantially surrounding the central portion 372 and positioned between the central portion 372 and the periphery 370. The border 376 may be free of the apertures 374. The tissue interface 308 may be adapted to cover the tissue site as well as the tissue surrounding the tissue site, such that the central portion 372 of the tissue interface 308 is positioned adjacent to or proximate to the tissue site, and the periphery 370 is positioned adjacent to or proximate to tissue surrounding the tissue site. Further, the apertures 374 in the tissue interface 308 may be in fluid communication with the tissue site and tissue surrounding the tissue site. In some embodiments, the dressing 302 may further include an additional structure for placement against or within the tissue site, such as a wound filler.
The apertures 374 in the tissue interface 308 may have any shape, such as for example, circles, squares, stars, ovals, polygons, slits, complex curves, rectilinear shapes, triangles, or other shapes. As shown in
In some embodiments, the plurality of apertures 374 positioned in the periphery 370 of the tissue interface 308 may be apertures 374a. Additionally, the plurality of apertures 374 positioned in the central portion 372 of the tissue interface 308 may be apertures 374b. Each of the apertures 374a and 374b may vary in size. However, in some embodiments, the apertures 374a may have a diameter between about 9 millimeters to about 11 millimeters. The apertures 374b may have a diameter between about 1.5 millimeters to about 3 millimeters. Furthermore, the spacing between each of the apertures 374a and 374b may also vary depending on the specific embodiment. For example, in some embodiments, the diameter of each of the apertures 374a may be separated from one another by a distance of between about 2.5 millimeters to about 3.5 millimeters. Further, a center of one of the apertures 374b may be separated from a center of another of the apertures 374b in a first direction by a distance of between about 2.5 millimeters to about 3.5 millimeters. In a second direction transverse to the first direction, the center of one of the apertures 374b may be separated from the center of another of the apertures 374b by a distance of between about 2.5 millimeters to about 3.5 millimeters. As shown in
The tissue interface 308 may be a soft, pliable material suitable for providing a fluid seal with a tissue site. For example, the tissue interface 308 may comprise a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gel, a foamed gel, a soft closed-cell foam such as polyurethanes and polyolefins coated with an adhesive, polyurethane, polyolefin, or hydrogenated styrenic copolymers. The tissue interface 308 may have a thickness between about 500 micrometers and about 1,000 micrometers. Further, in some embodiments, the tissue interface 308 may be comprised of hydrophobic or hydrophilic materials.
In some embodiments (not shown), the tissue interface 308 may be a hydrophobic-coated material. For example, the tissue interface 308 may be formed by coating a spaced material, such as, for example, woven, nonwoven, molded, or extruded mesh with a hydrophobic material. The hydrophobic material for the coating may be a soft silicone, for example.
The adhesive 378 may be in fluid communication with the plurality of apertures 374 in at least the periphery 370 of the tissue interface 308. In this manner, the adhesive 378 may be in fluid communication with tissue surrounding a tissue site through the plurality of apertures 374 in the tissue interface 308. The adhesive 378 may extend or be passed through the plurality of apertures 374 to contact epidermis for securing the cover 306 to, for example, tissue surrounding a tissue site. The plurality of apertures 374 may provide sufficient contact of the adhesive 378 to the epidermis to secure the cover 306 about a tissue site. The plurality of apertures 374 and the adhesive 378 may also be configured to permit release and repositioning of the cover 306 about a tissue site.
In some embodiments, an additional or alternative attachment device may be used to secure the cover 306 about the tissue site. For example, double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel may be used. Furthermore, thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve seals and to reduce leaks. Additionally, any of the plurality of the apertures 374 may be adjusted in size and number to maximize the surface area of the adhesive 378 in fluid communication through the plurality of the apertures 374 for a particular application or geometry of the tissue interface 308.
The adhesive 378 may be a medically-acceptable adhesive. The adhesive 378 may also be flowable. For example, the adhesive 378 may comprise an acrylic adhesive, rubber adhesive, high-tack silicone adhesive, polyurethane, or other adhesive substance. In some embodiments, the adhesive 378 may be a pressure-sensitive adhesive, such as an acrylic adhesive with coating weight of 15 grams/m2 (gsm) to 70 grams/m2 (gsm). The adhesive 378 may be a layer having substantially the same shape as the periphery 370 of the tissue interface 308, and thus have a large central aperture, as shown in
Factors that may be utilized to control the adhesion strength of the cover 306 may include the diameter and number of the plurality of the apertures 374 in the tissue interface 308, the thickness of the tissue interface 308, the thickness and amount of the adhesive 378, and the tackiness of the adhesive 378. An increase in the amount of the adhesive 378 extending through the plurality of the apertures 374 may correspond to an increase in the adhesion strength of the cover 306. A decrease in the thickness of the tissue interface 308 may correspond to an increase in the amount of adhesive 378 extending through the plurality of the apertures 374. Thus, the diameter and configuration of the plurality of the apertures 374, the thickness of the tissue interface 308, and the amount and tackiness of the adhesive 378 utilized may be varied to provide a desired adhesion strength for the cover 306. For example, in some embodiments, the thickness of the tissue interface 308 may be about 200 micrometers, the adhesive 378 may be a layer having a thickness of about 30 micrometers and a tackiness of 2000 grams per 25 centimeter wide strip, and the diameter of the apertures 374a in the tissue interface 514 may be about 10 millimeters.
Still referring primarily to
The peripheral portions of the cover 306 may be positioned proximate to the periphery 370 of the tissue interface 308 such that a central portion of the cover 306 and the central portion 372 of the tissue interface 308 define an enclosure. The adhesive 378 may be positioned at least between the peripheral portions of the cover 306 and the periphery 370 of the tissue interface 308. The cover 306 may cover the tissue site and the tissue interface 308 to provide a fluid seal and a sealed space between the tissue site and the cover 306. Further, the cover 306 may cover other tissue, such as a portion of epidermis, surrounding the tissue site to provide the fluid seal between the cover 306 and the tissue site. In some embodiments, a portion of the peripheral portion of the cover 306 may extend beyond the periphery 370 and into direct contact with tissue surrounding the tissue site. In some embodiments, the peripheral portion of the cover 306, for example, may be positioned in contact with tissue surrounding the tissue site to provide the sealed space without the tissue interface 308. Thus, the adhesive 378 may also be positioned at least between the peripheral portion of the cover 306 and tissue, such as the epidermis, surrounding the tissue site. The adhesive 378 may be disposed on a surface of the cover 306 adapted to face the tissue site and the tissue interface 308. Additionally, the cover 306 may include an aperture 380, which in some embodiments may be generally positioned in a central portion of the cover 306. The aperture 380 may allow for fluid communication between a sealed space provided by the cover 306 and including a tissue site, and one or more conduits for conducting negative pressure and/or for delivering therapeutic fluids to the tissue site.
The cover 306 may be formed from any material that allows for a fluid seal, such as any of the materials of the cover 106. The cover 306 may be vapor permeable and liquid impermeable, thereby allowing vapor and inhibiting liquids from exiting the sealed space provided by the cover 306. In other embodiments, a low or no vapor transfer drape might be used. The cover 306 may comprise a range of medically suitable films having a thickness between about 15 microns (μm) to about 50 microns (μm). The tissue interface 308 may be adapted to transfer fluid away from a tissue site rather than store the fluid. For example, as fluid, such as wound exudate, is drawn away from a tissue site, the fluid may pass through the tissue interface 308 in response to the application of negative pressure to the dressing 302, and travel upwards towards the cover 306. Once the fluid reaches the cover 306, the fluid may be drawn through the aperture 380 in the cover 306, out of the dressing 302, and into a fluid conductor, such as the conduit 128 of
The diagnostic module 340 may be positioned within the dressing 302, more specifically between the tissue interface 308 and the cover 306. The diagnostic module 340 may be positioned so that as the tissue interface 308 comes into contact with fluid from a tissue site, the fluid may pass through the apertures 374 of the tissue interface 308 and come into contact with the diagnostic module 340. As the fluid from the tissue site comes into contact with the one or more sensors of the diagnostic module 340, the sensors may detect and/or measure one or more parameters related to the tissue site, such as for example, pH, temperature, humidity, as well as others.
Similarly, in some embodiments, the second sensor 554 of the central sensor device 542, the second sensor 564 of the first remote sensor device 544, and the second sensor 574 of the second remote sensor device 546 may be selected or configured to detect and/or measure a second parameter. In one example embodiment, each of the first sensors 552, 562, and 572 may be configured to measure pH level, for example the pH level of wound exudates that come into contact with each of the first sensors 552, 562, and 572, while each of the second sensors 554, 564, and 574 may be configured to measure the oxygen concentration within the portion of the dressing 102 or therapy system 100 adjacent to each of the second sensors 554, 564, and 574. Additionally, the third sensor 556 of the central sensor device 542 may be configured to measure a third parameter, for example temperature, in the vicinity of the central sensor device 542, while the fourth sensor 558 may be configured to measure a fourth parameter, for example the glucose level, in wound exudates that come into contact with the central sensor device 542. It should be noted that any or all of the individual sensors discussed with respect to each of the central sensor device 542, the first remote sensor device 544, and second remote sensor device 546 may be configured or interchanged with other sensors to detect and/or measure a different one or more parameters. Furthermore, additional remote sensor devices, which may include additional sensors, such as a fourth remote sensor device (not shown) and a fifth remote sensor device (not shown) may be included to detect and/or measure either the same parameter(s) as the central sensor device or a different one or more parameter(s).
Still referring primarily to
The central sensor device 542 may also include a processing unit 566 for receiving and processing signals and data from each of the sensors onboard the central sensor device 542. Thus, in the example embodiment shown in
Still referring primarily to
As mentioned, the remote sensor devices, such as the first remote sensor device 644 and the second remote sensor device 646, may include individual sensors that measure parameters different from those measured by the sensors of the central sensor device 642. Thus, in some embodiments, the first remote sensor device 644 may include a first sensor 662 and a second sensor 664 that are configured to measure a third parameter and a fourth parameter, respectively. Similarly, the second remote sensor device 646 may include a first sensor 672 and a second sensor 674 that are also configured to measure the third parameter and the fourth parameter, respectively. Meanwhile, the first sensor 652 and the second sensor 654 of the central sensor device 642 may be configured to measure a first parameter and a second parameter, respectively. Also worth noting, in some embodiments, the sensors of the second remote sensor device 646 may be configured to measure parameters different from the sensors of the first remote sensor device 644 and the central sensor device 642. Thus, in some embodiments, the sensors, such as the first sensor 672 and the second sensor 674, of the second remote sensor device 646 may be configured to measure a fifth parameter and a sixth parameter, respectively. The sensor devices of the diagnostic module 640, such as the central sensor device 642, the first remote sensor device 644, and the second remote sensor device 646 may otherwise include analogous features and operate analogously to the sensor devices of the diagnostic module 540.
Still referring to
In operation, the therapy system 100 and its various components and features may be used in accordance with the exemplary operating method 900 illustrated in
Once the diagnostic module 140 of the therapy system 100 has begun transmitting data from the one or more sensors, the controller 110 of the therapy system 100 may receive and process the data, as depicted in step 908 of method 900. The controller 110 of the therapy system 100 may then determine whether the one or more parameters detected and/or measured by the sensor(s) of the diagnostic module 140 fall within an acceptable range, as shown in step 910. Should the controller 110 determine that the one or more measured parameters are within an acceptable range, the controller 110 may determine, as depicted in step 912, whether the desired therapy for the tissue site 150 has been completed. In some embodiments, if the controller 110 determines that therapy has been completed, the delivery of therapy, such as negative-pressure therapy, may be ceased, as depicted in step 914. However, should the controller 110 determine in step 912 that therapy has not been completed, the therapy system 100 will continue to operate to deliver therapy, and the controller 110 may continue to receive and process data from the diagnostic unit 140, according to steps 908 and 910.
Returning to step 910 of method 900, should it be determined by the controller 110 that the one or more measured parameters are not within an acceptable range, the controller 110 may then determine whether an adjustment to the provided therapy or whether an additional form of therapy is necessary or would be beneficial, as shown in step 916. If it is determined that no adjustment of therapy or additional form(s) of therapy is necessary, the controller 110 may then determine whether an alert should be generated for a user of the therapy system 100 to indicate that one or more parameters are outside of an acceptable range, as shown in step 918. Depending on the particular parameter that falls outside of a prescribed range, the therapy system 100 may also be configured to determine whether a visual or audible alarm should be generated. Such a user alert and/or alarm may then be generated, as illustrated in step 924. Regardless of whether an alert or alarm is generated, the controller 110 may then determine whether therapy should be discontinued given that one or more measured parameters is out of an acceptable range, as shown in step 920. If therapy is to be discontinued, the therapy system 100 may cease to provide therapy, and in some instances, a report indicating the status of the measured parameters along with other operational data may be generated, as illustrated in step 922. Otherwise, the therapy system 100 may continue to provide therapy, and the controller 110 may return to step 908 of method 900.
Referring back to step 916, should the controller 110 determine that an adjustment to therapy is warranted, the controller 110 may then proceed to a series of decision points to determine which type or types of therapy adjustments are needed. For example, as shown in step 926, the controller 110 may assess whether the amount of negative-pressure therapy should be adjusted, and if it is determined that an adjustment is needed, may make such an adjustment as shown in step 932. Additionally, the controller 110 may determine whether an adjustment to fluid instillation therapy is warranted, as depicted in step 928, which in some embodiments may result in the amount of instillation fluid, such as saline solution, to be increased, reduced, or stopped, as depicted in step 934. Further, the controller 110 may also determine whether one or more additional treatment compounds should be administered, as shown in step 930. For example, the controller 110 may determine that an antimicrobial compound should be delivered to the tissue site 150, in which case, as part of step 936, such a compound may be added to the instillation fluid being administered to the tissue site 150.
Regardless of the outcome of the decision points illustrated in steps 926, 928, and 930, the controller 110 may then determine, as depicted in step 938, whether one or more user alerts should be generated. Such an alert may then be subsequently generated and/or a report generated for a user, as shown in step 940. Regardless of such an alert, the therapy system 100 may then continue to operate according to the adjustments needed and determined by the various steps of the method 900, with the controller returning to step 908 to continue to receive and analyze diagnostic data and repeating the subsequent steps in method 900 until it is determined that therapy is completed at one of the appropriate decision points.
The systems, apparatuses, and methods described herein may provide significant advantages. For example, currently, it may be challenging for clinicians to recognize conditions, such as infection, at a tissue site undergoing negative-pressure therapy or fluid instillation therapy. As a result, appropriate adjustments to therapy or administration of additional therapeutic compounds, such as antimicrobial solutions to treat or prevent infection, may not always take place as quickly as desired. Therefore, by providing a therapy system that incorporates real-time diagnostic feedback with respect to parameters at a tissue site, clinicians may be better alerted to developing or changing conditions at the tissue site. Additionally, the therapy systems disclosed herein may also provide output recommendations to users, such as clinicians, for adding, adjusting, or suspending one or more forms of therapy based on the diagnostic feedback.
Furthermore, while many negative-pressure wound therapy systems currently will provide a set therapy based on settings made by a clinician, typically no adjustments to the therapy are made until the system is attended to by a caregiver or other operator. Thus, adjustments are often not made until later time points when a tissue site, such as a wound, can be assessed and alterations to therapy made, if required. As an improvement or solution to this outstanding need, the systems and devices of the present disclosure may offer the ability to incorporate real-time diagnostic feedback into a therapy system, and may further enable improved and automated decision-making for administering therapy to a tissue site. Thus, a fully-automated therapy system with functions such as automated control of negative-pressure therapy and fluid instillation therapy, as well as delivery of one or more therapeutic compounds, may be provided. By including the capability of gathering real-time feedback data from a diagnostic module worn in proximity to the tissue site, therapy adjustments may be quickly made by the therapy system, in some cases almost instantaneously. Operators of therapy systems with such diagnostic capabilities may also be provided with improved information regarding the condition of the tissue site, and therefore may be empowered to more quickly make better decisions regarding therapy applied to the tissue site.
Also worth noting is that the designs and solutions disclosed herein may be sealable so that the therapy system 100 may be able to detect variables associated with multiple tissue sites and/or dressings, and simultaneously administer one or more appropriate forms of therapy to those respective tissue sites. For Example, a single therapy unit 101, such as a V.A.C.ULTA™ Unit, may receive feedback from a diagnostic module 140 having remote sensors positioned at multiple tissue sites, and may administer the same or different forms of negative-pressure and/or fluid instillation therapy to the tissue sites based on the respective feedback(s) from the different remote sensors.
While shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described herein are susceptible to various changes and modifications. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles “a” or “an” do not limit the subject to a single instance unless clearly required by the context. Components may be also be combined or eliminated in various configurations for purposes of sale, manufacture, assembly, or use. For example, in some configurations the dressing 102, the container 112, or both may be eliminated or separated from other components for manufacture or sale. In other example configurations, the controller 110 may also be manufactured, configured, assembled, or sold independently of other components.
The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.
This application claims the benefit, under 35 USC 119(e), of the filing of U.S. Provisional Patent Application Ser. No. 62/617,487, entitled “WOUND SENSOR AND DIAGNOSTICS SYSTEM FOR WOUND THERAPY APPLICATIONS,” filed Jan. 15, 2018, which is incorporated herein by reference for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2019/013634 | 1/15/2019 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62617487 | Jan 2018 | US |
